4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Obesity by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1072 ongoing clinical trials involving Obesity
Of the 1072 trials,368 trials are in Phase III
Furthermore, 328 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Obesity by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Obesity, a Metabolic Disorder condition. The largest number of ongoing clinical trials for Obesity is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Obesity-related drug trials.

Norwegian University of Science and Technology: The leading ongoing Obesity related clinical trial sponsor

Norwegian University of Science and Technology is the top sponsor for Obesity-related ongoing clinical trials.

Novo Nordisk AS, Yale University, Eli Lilly and Co and University of Colorado Denver are among other notable clinical trial sponsors involved in Obesity. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Obesity

Liraglutide (Saxenda), Lorcaserin hydrochloride (Belviq, Venespri, APD356) and Bupropion hydrochloride and Naltrexone (Contrave, Mysimba) are among the key marketed drugs involving Obesity.

Liraglutide (Saxenda) an analog of human GLP-1 acts as an antiobesity agent. It functions via Glucagon Like Peptide 1 Receptor (GLP1R) Agonist mechanism of action. Liraglutide is formulated as solution for subcutaneous route of administration. Liraglutide was first approved in 2014 and is marketed globally in the US, UK, Australia, Russia, Germany, and France by Novo Nordisk Inc and its subsidiaries.

Lorcaserin hydrochloride (Belviq, Venespri, APD356) is an antiobesity agent. It functions via 5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxytryptamine Receptor 1C or Serotonin Receptor 2C or HTR2C) Agonist mechanism of action. Lorcaserin hydrochloride is formulated as film coated tablets and tablets for oral administration. Lorcaserin hydrochloride was first approved in 2012 and is marketed in the US, Brazil, Israel, Mexico and South Korea by several prominent pharma giants including Eisai Inc.